Ellen Snow - Dec 3, 2021 Form 4 Insider Report for Pear Therapeutics, Inc. (PEARQ)

Role
Chief Accounting Officer
Signature
/s/ Stacie S. Aarestad, Attorney-in-Fact
Stock symbol
PEARQ
Transactions as of
Dec 3, 2021
Transactions value $
$0
Form type
4
Date filed
12/7/2021, 04:26 PM
Next filing
Feb 18, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PEARQ Stock Option (Right to Buy) Award +265K 265K Dec 3, 2021 Common Stock 265K $1.40 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying the option vested or shall vest on March 29, 2022 and an additional 2.0833 and 1/3% of the shares vested or shall vest on the last day of each calendar month thereafter.
F2 Received in accordance with the terms of the Business Combination Agreement (the "Business Combination Agreement") dated as of June 21, 2021, by and among Thimble Point Acquisition Corp., Oz Merger Sub, Inc. and Pear Therapeutics (US), Inc. (f/k/a Pear Therapeutics, Inc.) ("Private Pear"), in exchange for an option to acquire 180,000 shares of common stock of Private Pear for $2.06 per share.